Sharenet Sites 
Sharenet Sites
Acquisition of a portfolio of products from MSD-All conditions precedent met
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen Holdings”)
FURTHER ANNOUNCEMENT REGARDING THE ACQUISITION FROM MSD OF A PORTFOLIO OF PRODUCTS
BY ASPEN - CONDITIONS PRECEDENT MET
Shareholders are referred to the announcements released by Aspen Holdings on 27 June, 1 October and
31 October 2013 wherein it was confirmed, inter alia, that Aspen had reached an agreement on an option
granted to Aspen Global Incorporated (“AGI”) to acquire a portfolio of 11 branded finished dose form
molecules (“the Products”) from MSD, covering a diverse range of therapeutic areas and including products
that use APIs manufactured by the API Business recently acquired from MSD. It was also confirmed that
AGI had, subsequently, exercised the option to acquire the Products on 31 October 2013 and that, subject
to the fulfilment of certain conditions precedent, the effective date of the Product transaction resulting
from the exercise of the option would be 31 December 2013.
Aspen is pleased to confirm that all the contractual conditions precedent in respect of the Product
acquisition have been met and that the acquisition of the Products will complete today, 31 December
2013.
Durban
31 December 2013
Underwriters
The Standard Bank of South Africa Limited
Bank of America, N.A.
Mandated Lead Arrangers and Bookrunners
The Standard Bank of South Africa Limited
Banc of America Securities Limited
Sponsor:
Investec Bank Limited
Date: 31/12/2013 11:01:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
